Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients-Reference-Cited by-同舟云学术

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients

Published:2013-11-20 Issue:11 Volume:8 Page:e79732
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rolfs Arndt,Giese Anne-Katrin,Grittner Ulrike,Mascher Daniel,Elstein Deborah,Zimran Ari,Böttcher Tobias,Lukas Jan,Hübner Rayk,Gölnitz Uta,Röhle Anja,Dudesek Ales,Meyer Wolfgang,Wittstock Matthias,Mascher Hermann

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals;RY Wang;Genet Med,2011

2. Newborn screening for lysosomal storage disorders in Hungary;J Wittmann;JIMD Reports,2012

3. Newborn screening for lysosomal storage disorders;K Nakamura;Am J Med Genet C Semin Med Genet,2011

4. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies;JM Aerts;J Inherit Metab Dis,2011

5. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose – response relationships;CE Hollak;Expert Opin Pharmacother,2009

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review;Molecular Genetics and Metabolism;2024-09

2. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy;Biomolecules;2024-07-12

3. Unraveling the diagnostic enigma: laboratory diagnosis of sphingolipid activator protein deficiencies;Journal of Laboratory and Precision Medicine;2024-07

4. A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy;Journal of Clinical Medicine;2024-06-05

5. Neuronopathic Gaucher disease: Rare in the West, common in the East;Journal of Inherited Metabolic Disease;2024-05-20